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Generation of induced cardiomyocytes (iCMs) directly from fibroblasts offers a great opportunity for cardiac disease
modeling and cardiac regeneration. A major challenge of iCM generation is the low conversion rate. To address this issue,
we attempted to identify small molecules that could potentiate the reprogramming ability towards cardiac fate by removing
inhibitory roadblocks. Using mouse embryonic fibroblasts as the starting cell source, we first screened 47 cardiac
development related epigenetic and transcription factors, and identified an unexpected role of H3K4 methyltransferase
Mll1 and related factor Men1 in inhibiting iCM reprogramming. We then applied small molecules (MM408 andMI503) of
Mll1 pathway inhibitors and observed an improved efficiency in converting embryonic fibroblasts and cardiac fibroblasts
into functional cardiomyocyte-like cells. We further observed that these inhibitors directly suppressed the expression of
Mll1 target gene Ebf1 involved in adipocyte differentiation. Consequently, Mll1 inhibition significantly decreased the
formation of adipocytes during iCM induction. Therefore, Mll1 inhibitors likely increased iCM efficiency by suppressing
alternative lineage gene expression. Our studies show that targeting Mll1 dependent H3K4 methyltransferase activity
provides specificity in the process of cardiac reprogramming. These findings shed new light on the molecular mechanisms
underlying cardiac conversion of fibroblasts and provide novel targets and small molecules to improve iCM reprogramming
for clinical applications.
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Introduction
Heart disease is the leading cause of death in the
United States and around the world [1]. On heart
injuries, such as myocardial infarction, millions of
cardiomyocytes undergo irreversible necrosis and
infarct areas are replaced with fibroblasts and further
differentiate into nonfunctional tissues like fibrotic
scar [2] or adipose tissue [3, 4]. Recently, targeting
fibroblasts by introduction of three transcription
factors Gata4, Mef2C and Tbx5 (G, M and T), and
reprogramming them into cardiomyocyte-like cells
have shown therapeutic potential [5–8]. However,
direct reprogramming of fibroblasts into functional
cardiomyocytes with high efficiency remains a
challenge.
Numerous strategies have been applied to achieve
better efficiency of induced cardiomyocyte (iCM)
reprogramming. One strategy is to supply/introduce
additional transcription factors to the cocktail.
It has been shown that adding Hand2 [9], Nkx2-5 [10],
Correspondence: Zhong Wang
Tel: +1-734-763-3691
E-mail: zhongw@med.umich.edu.
Received 28 August 2016; accepted 5 September 2016
Citation: Cell Discovery (2016) 2, 16036; doi:10.1038/celldisc.2016.36
www.nature.com/celldisc
Mesp1, MyoCD or Baf60c [11] can increase the
reprogramming efficiency and/or improve functional
properties of iCMs. Although multiple combinations
have been used for reprogramming, Mef2C, Gata4 and
Tbx5 (MGT) seem to be irreplaceable. Furthermore,
stoichiometric expression of G, M, T proteins also
affects the efficiency of MGT-mediated reprogram-
ming [7]. Other strategies include application of Akt1
[12] or TGF-beta and Rho-associated kinase [13]
to inhibit pro-fibrotic signaling. Two microRNAs,
mir-1 and mir-133, when used in combination
with transcription factors, could also increase iCM
reprogramming efficiency [13–15].
Cardiac reprogramming is a process involving
extensive epigenetic changes [16]. Therefore, modulat-
ing epigenetic changes is an effective strategy to
improve efficiency. Successful examples include the
application of inhibitors of Ezh2 methyltransferase
and G9a histone methyltransferase [17] and shRNA-
mediated knockdown of Bmi1, a regulatory
component of polycomb complex involved in gene
silencing [18].
Another potential novel strategy to achieve more
specificity is to block conversion of fibroblasts into
non-myocytes during iCMs induction. The induction
of unexpected cell types in reprogramming appears to
be rather common. It has been observed that Ascl1
promotes both neuron and myocyte identities in direct
reprogramming from fibroblasts to neurons [19]. A
recent study also shows that Yamanaka factor-directed
iPSC reprogramming induces extraembryonic endo-
derm stem cells [20]. During iCM reprogramming, the
binding of transcription factor to non-cardiac specific
promoter can induce non-cardiac gene expression and
likely leads to differentiation of unexpected cell types
[21, 22]. Therefore, identifying epigenetic factors and
related small molecules to block lineage conversion
into non-cardiomycoyte cell types may in turn promote
iCMs formation.
In this report, we used a gain-of-function screen to
identify regulatory factors involved in iCM repro-
gramming, which revealed an unexpected role of Mll1
H3K4 methyltransferase and related co-activator
Men1 in inhibiting iCM formation. We demonstrated
that addition of Mll1 inhibitor MM408 converted
embryonic fibroblasts into functional cardiomyocyte-
like cells with a much higher efficiency. Furthermore,
we identified Ebf1, a key factor involved in adipocyte
differentiation, as a target of Mll1 during iCM repro-
gramming. Consequently, we observed that MM408
treatment during reprogramming inhibited adipocyte
related gene expression and adipocyte formation
and guided more cells into cardiomyocyte lineage.
These findings provide novel insights into the mole-
cular mechanisms of iCM reprogramming and identify
small molecules for improved iCM generation.
Results
Gain-of-function screen identified menin1 (Men1) as a
barrier to iCM reprogramming
To identify potential transcription and epigenetic
regulators of iCM reprogramming, we employed a
gain-of-function approach to explore the function of
47 genes (Figure 1a). On the basis of RNA-seq
data of cardiac cell differentiation [23], we cloned
47 transcription and epigenetic regulators highly
expressed in the cardiac progenitor and neonatal
cardiomyocytes stage into a pCW57.1 based lentivirus
vector pool (Supplementary Table S1). The individual
genes were then transduced into mouse embryonic
fibroblasts (MEFs) from a transgenic α-muscle
heavy chain (αMHC)-green fluorescent protein (GFP)
reporter mouse [5, 7] together with retroviruses
expressing polycistronic Mef2c/Gata4/Tbx5 (MGT)
[7]. Ten days after transduction, activation of GFP was
used to evaluate the efficiency of reprogramming
(Figure 1b). For the MGT plus empty pCW57.1 group,
we observed 11% GFP positive cells as reported pre-
viously, indicating similar successful rate for repro-
gramming (Figure 1c). Furthermore, we also observed
the enhancing effect of Hand2, Mesp1 and Baf60c as
reported [9, 11] (Figure 1b). Among the 47 candidate
regulators, overexpression of epigenetic regulators
Men1 and Suv39h1 resulted in fivefold and threefold
reduction in αMHC-GFP+ cells (Figure 1b). Flow
cytometry detected 3.9 and 4.5% of αMHC-GFP+ cells
in MGT+ Men1 and MGT+ Suv39h1 groups, respec-
tively (Figure 1c). Quantitative real-time PCR (QPCR)
results indicated that key cardiac genes Actc1 and
Tnnt2 were reduced following Men1 or Suv39h1
overexpression (Figure 1d). These results showed that
Men1 and Suv39h1 were barriers to iCM
reprogramming.
Men1 inhibited reprogramming through Mll1
Men1 is related to histone marks H3K9me3 and
H3K4me3 [24, 25], and Suv39h1 is a regulator for
H3K9me3 [26] (Figure 2a). As H3K9me3 has been
known as a repressive marker, we postulated that
Men1 might inhibit reprogramming through activating
H3K9 methyltransferase activity. Therefore, we
applied Suv39h1 inhibitor chaetocin [27] and Men1
inhibitor MI503 [28] in our reprogramming assays.
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Surprisingly, we did not observe any improvement in
reprogramming with addition of Suv39h1 inhibitor
chaetocin, but observed 1.5-fold increase with Men1
inhibitor MI503 (Figure 2b). Because MI503 targets
Men1 by blocking the binding of Men1 to the Mll1 and
Mll2 complex (Figure 2a) [28], Men1 likely affected
reprogramming by activating Mll1/2-related H3K4
methyltransferase activity, instead of repressing
H3K9me methyltransferase activity.
Histone H3K4methylations are generally associated
with gene activation, therefore our finding that inhi-
biting the activity of Mll1 H3K4 methyltransferase
enhanced cardiac reprogramming was surprising. To
confirm that MI503 increased reprogramming through
inhibiting Mll1-related H3K4me3 activity, we applied
a novel Mll1 complex-specific inhibitor in our system.
MM408 [29] compound is a modified version of the
previously reported MM401 [30] that disrupts the
interaction of WDR5 with Mll1 with higher binding
affinity (Figure 2c). It specifically inhibits Mll1-related
H3K4 methyltransferase activity without affecting the
activities of other Mll family proteins. Indeed, MM408
inhibitor increased reprogramming efficiency in a dose
dependent manner (Figure 2d). Overall, 17.5 μM or
35 μM MM408 resulted in the highest iCM conversion
rate, whereas 70 μM MM408 resulted in potential
toxicity and lowered the conversion rate. Also, 17.5 μM
MM408 led to a significantly higher iCM conversion
rate compared with optimized 1 μM MI503 (Figure 2e).
In addition, Mll1 shRNA knockdown also resulted in
elevated iCM conversion rate (Figure 2e). Collectively,
these results suggested that inhibiting Mll1 activities
Figure 1 Gain-of-function screen identified Men1 as a barrier of iCM reprogramming. (a) A schematic diagram of the
gain-of-function screen strategy. Cloned individual gene was transduced into MEFs derived from a transgenic αMHC-GFP
reporter mouse together with retroviruses expressing polycistronic MGT. Medium was changed every 2 days. Activation of GFP
was evaluated 10 days after transduction by flow cytometry. (b) Column graph of normalized percentages of αMHC-GFP+, green
arrow pointing at the fold change of Men1 and Suv39h1. (c) Representative flow cytometry results of Men1 and Suv39h1 groups
shown by histogram (upper panel) and flow plots (lower panel). For the MGT plus empty pCW57.1 group, 11% GFP positive cells
were detected by flow cytometry. For MGT+ Men1 and MGT+ Suv39h1 groups, 3.9 and 4.5% of αMHC-GFP+ cells were
detected, respectively. (d) Relative expression of cardiomyocytes marker genes Tnnt2 and Actc1 in MEFs infected with MGT
combined with Men1, Suv39h1 or empty vector after 10 days. Untransduced MEFs were used as a negative control (MEF).
Error bars indicate mean± s.e.m.; *Po0.05, **Po0.01, ***Po0.001.
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by applying small molecules MI503 and MM408
increased the reprogramming efficiency.
Mll1 inhibitors significantly enhanced cardiac
reprogramming
We next investigated the effect of Mll1 inhibition on
the functional properties of iCMs. As MM408 resulted
in the highest iCM conversion rate compared with
other inhibitors, we focused on MM408 in our
following experiments. Owing to its near highest iCM
conversion rate and low cell toxicity, 17.5 μM MM408
was used in these experiments (Figure 2). We first
performed molecular characterizations of the
MM408-treated and untreated cells by examining the
expression of a panel of sarcomeric, contractility and
ion channel genes. The results revealed a higher
expression of these functionally important cardiac
genes especially Actc1, Scn5a and Myh6 in the
MM408-treated group (Figure 3a). In addition,
MM408-treated cells showed reduced expression of
genes associated with the fibroblast lineage. To test
whether treatment of MM408 promotes iCM
maturation, we then examined the structural properties
using immunostaining against cardiac Troponin
T (cTnT) and sarcomeric α-actinin, two specific
components of sarcomere in cardiomyocyte.
Immunostaining against these two proteins could
clearly show the sarcomeric structure. Treatment with
MM408 for 2 weeks significantly increased the number
of cells with assembled sarcomeric structures compared
Figure 2 Mll1 inhibitors significantly enhanced cardiac reprogramming. (a) A diagram depicting the interaction of Men1 with Mll1
complex and Men1 with Suv39h1. The target sites of small molecules have been marked with arrows. (b) The effect of Suv39h1
inhibitor chaetocin and Men1 inhibitor MI503 treatment on iCM reprogramming. Relative fold changes of αMHC-GFP+ were
normalized to MGT induction with DMSO treatment. (c) The chemical structure of MM408. (d) Optimization of Mll1 inhibitor
MM408 treatment for improving reprogramming indicated by the fold change of αMHC-GFP+ cells. (e) The effect of MI503,
MM408 and Mll1 shRNA on iCM reprogramming indicated by the fold change of αMHC-GFP+ cells in MGT-transduced MEFs.
Non-targeting (NT) shRNA was used as control for Mll1 shRNA. Error bars indicate mean± s.e.m.; *Po0.05, **Po0.01,
***Po0.001.
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with the control group (Figure 3b; Supplementary
Figure S1). Flow cytometric analyses further con-
firmed that MM408 induced higher cTnT expression.
In particular, we observed that 25% of the cells became
GFP positive and 30% of the cells became cTnT
positive in MM408-treated group, more than twofold
increase over non-MM408-treated group (Figure 3c).
Notably, 10% GFP and cTnT double positive cells
were observed, indicating a more than threefold
increase over controls.
Furthermore, we evaluated the presence of beating
iCMs in our reprogramming assays using the beating
protocol as reported [31]. Spontaneously contracting
cells were apparent 3 weeks after MM408 treatment
indicating that MM408 treatment significantly
increased beating iCMs (Supplementary Movies S1
and S2). Approximately 92 beating loci per well were
identified in MM408-treated group 4 weeks after
transduction (Figure 3d). In contrast, only 20 beating
loci were observed in non-MM408-treated group.
To further assess the functionality of MM408-treated
iCMs, we next analyzed intracellular Ca2+ flux by
Rhod3 dye labeling 4 weeks after reprogramming.
MM408-treated iCMs showed significantly higher
spontaneous Ca2+ oscillations with various frequencies
compared with control group (Figure 3e; Supplementary
Movies S3 and S4), as previously reported in our
reprogrammed iCMs [7, 18]. By using neonatal cardiac
fibroblast instead of MEFs transduced with MGT, we
also observed more beating loci in MM408-treated
Figure 3 Mll1 inhibitor MM408 improved functional properties of induced cardiomyocytes. (a) Relative expression of CM and
fibroblast marker genes in neonatal whole heart isolated from postnatal day 0 (P0) mice and DMSO or MM408-treated iCMs
10 days after MGT transduction. Statistic analyses were performed between MM408- treatment and DMSO-treatment groups.
(b) Immunocytochemistry (ICC) of cardiac markers α-actinin of MGT-transduced cells with or without MM408 treatment by
fluorescence microscopy (400 × ). The right panels were enlarged areas from the left panels. (c) Quantification for αMHC-GFP+
and cTnT+ cells or double positive cell detected by flow cytometry 10 days after transduction. (d) Quantification of the number of
beating iCMs loci with indicated viral infection and small molecule treatment for 4 weeks (n = 10). (e) Quantification of
spontaneous Ca2+ oscillations cells per field with indicated viral infection and small molecule treatment for 4 weeks (n = 50 from
10 wells). Untransduced MEFs were used as a negative control (MEF). Error bars indicate mean± s.e.m.; *Po0.05, **Po0.01,
***Po0.001.
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Figure 4Mll1 inhibitor guided cardiac reprogramming by suppressing ectopic adipocyte related gene expression. (a) The effect of
timing and duration of WDR5 inhibitor MM408 treatment on iCM reprogramming, as shown by the fold change of αMHC-GFP+
cells after MGT transduction. Mll1 inhibitor was added with various time durations after viral transduction: D1-, from day 1 until
detection; D3-, from day 3 until detection; D5-, from day 5 until detection; D1-3, from day 1 to day 3; D1-5, from day 1 to day 5;
D3-5, from day 3 to day 5. (b) Relative expression of cardiomyocyte (CM), fibroblast, adipocyte and smooth muscle cells (SMC)
marker genes in early stage of iCM reprogramming with either MM408 or DMSO treatment 3 days after MGT transduction.
Statistic analyses were performed between MEF with MM408-treated or DMSO-treated groups. Untransduced MEFs were used
as a negative control (MEF). (c) Gene Ontology (GO) enrichment analysis of down-regulated genes in Mll1 − /− MEFs. The list
shows enriched pathway ordered by P-value. The pathways related with Pparg and adipocyte lineage were marked in red. (d) Oil
Red O stain of adipocyte cells in MGT-transduced MEFs 14 days after transduction with or without MM408 treatment. (e)
Expression of Ebf1 during reprogramming in MGT-transduced MEFs, with or without MM408 treatment. The P-value reflecting the
statistical significant difference of the expression of Ebf1 at D11 was 0.0004. Untransduced MEFs were used as a negative
control (MEF). (f) The effect of Mll1 or Ebf1 knockdown on improving iCM efficiency indicated by the fold change of αMHC-GFP+
cells. Non-targeting (NT) shRNA was used as a control for Mll1 or Ebf1 shRNA. (g) A working model of MM408 mediated cardiac
reprogramming. Mll1 inhibitor MM408 promoted iCM conversion by suppressing adipocyte lineage gene expression. Error bars
indicate mean± s.e.m.; *Po0.05, **Po0.01, ***Po0.001.
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group compared with non-MM408-treated group
(Supplementary Figure S2; Supplementary Movies S5
and S6). These results revealed that MM408 not only
increased cardiac gene expression, but also enhanced
iCM function.
Mll1 inhibitor guided cardiac reprogramming by
suppressing adipocyte formation
To characterize the cellular and molecular
mechanisms of MM408/Mll1 action during iCM
induction, we set out to determine the timing of Mll1
inhibitor-mediated effects on iCM reprogramming
(Figure 4a). Fibroblasts were transduced withMGT on
day 0, andMM408 compound was added to the culture
medium at various time points. The most effective
time-window was to add MM408 from day 1, resulting
in three times as many GFP+ cells as negative control.
These results indicated that MM408 exerted its effect
from the initiation of reprogramming, consistent with
the idea that epigenetic repatterning occurs at early
stage of reprogramming [16, 18]. Therefore, we
attempted to identify the direct target(s) of Mll1 in
fibroblasts that mediate(s) its effect on iCM
reprogramming.
Given the fact that M, G and T are all potent
transcription factors that regulate multiple biological
processes during early embryonic development, it is
likely that during MGT-mediated iCM formation,
reprogramming factors not only activate cardiac
specific gene expression but also induce non-cardiac
lineage gene expression. To test this hypothesis, we
examined the expression of fibroblast-, adipocyte- and
SMC-related genes at the early stage of reprogramming
(3 days post transduction). We found that in the
early stage of reprogramming, overexpression of MGT
in fibroblasts led to not only elevated cardiac gene
expression but also increased adipocyte gene
expression 3 days post transduction. In contrast,
fibroblast or SMC-related genes in MM408-treated
and DMSO-treated groups did not change (Figure 4b).
By comparing the expression profiles of Mll1 − /− MEFs
versus Mll1+/+ MEFs [32] with gene ontology analysis,
we discovered that the down-regulated genes were
highly related to adipogenesis and peroxisome
proliferator-activated receptor pathways (Figure 4c).
Consistent with this observation, in Mll1 − /− MEFs,
numerous genes related to those functions were
down-regulated. More importantly, we observed
adipocyte-like cells and increased adipocyte formation
detected by Oil Red O stain 14 days after MGT
transduction (Figure 4d). These results suggested
that during reprogramming, ectopic expression of
adipocyte lineage genes might interfere with the
acquisition of cardiomyocyte cell fate in fibroblasts.
Therefore, we set out to test whether Mll1 inhibitors
enhanced cardiac reprogramming by inhibiting
adipocyte formation. On the basis of the fold change of
expression and our previous report that Mll1 directly
binds to Ebf1 gene locus in MEFs and embryonic stem
cells [32, 33], we propose that adipogenesis-related
Ebf1 could be a key target of Mll1 inhibitor in iCM
reprogramming as Ebf1 expression was elevated during
reprogramming (Figure 4e). In contrast, when MM408
was applied during iCM induction, expression of Ebf1
was dramatically decreased at day 11 post transduction
(Figure 4e). Furthermore, adipogenesis marker genes
Fabp4 and Pparg also exhibited a decreased expression
after MM408 treatment (Supplementary Figure S3).
Consistent with the decrease of adipogenesis-related
gene expression, Oil Red O staining detected a
significant decrease in adipocyte formation with
MM408 treatment (Figure 4d). To directly test if
blocking adipocyte lineage gene expression could pro-
mote iCM formation, we performed RNAi-mediated
knockdown of Ebf1 and Mll1 during iCM formation.
Indeed, knockdown of Ebf1 or Mll1 increased iCM
reprogramming efficiency (Figure 4f), indicating that
Mll1 inhibitor repressed adipocyte formation mainly
through blocking the expression of Ebf1. Altogether,
these results strongly suggested that inhibition of Mll1
promotes iCM conversion by suppressing adipocyte
lineage gene expression (Figure 4g).
Discussion
We report here an unexpected role of Mll1 and
related factor Men1 in cardiac reprogramming.
Application of novel small molecules MM408 and
MI503, inhibitors of Mll1 and Men1, resulted in much
higher efficiency of iCM formation from embryonic
fibroblasts. Mechanistically, these inhibitors directly
suppressed the expression of Mll1 target gene Ebf1,
a key gene involved in adipocyte differentiation. In
parallel with Mll1 inhibition, we observed decreased
formation of adipocytes in our iCM assays. Therefore,
Mll1 inhibitors increased iCM efficiency likely through
suppressing the expression of adipocyte lineage genes.
Our studies show that targeting Mll1-related H3K4
methyltransferase activity with Mll1 inhibitors pro-
vides more specificity in the process of iCM induction.
Given the well-established antagonistic roles of
TrxG and PcG complexes in development [34], our
discoveries that inhibiting the activities of both PcG
component Bmi1 and TrxG component Mll1 enhance
Liu Liu et al.
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iCM formation are surprising. However, our further
studies indicate that Mll1 and Bmi1 exert their
respective activating and repressive functions via
distinct mechanisms [18]. Specifically, reduced Bmi1
expression leads to increased levels of the active histone
mark H3K4me3 and reduced levels of repressive
H2AK199ub at cardiogenic loci, and de-repression of
cardiogenic gene expression [18]. In contrast, as
reported here, inhibiting Mll1 activity leads to
decreased expression of genes involved in adipocyte
formation and consequent low induction of adipocytes.
Therefore, seemingly opposite functions of epigenetic
factors may work together to facilitate reprogramming
or transdifferentiation. Future studies will determine
whether combined inhibition of Mll1 and Bmi1
could synergistically increase iCM conversion in a
time-window dependent fashion.
To our knowledge, this is the first study to show that
epigenetic factor/inhibitor can enhance cardiac repro-
gramming by blocking conversion of fibroblasts into
non-myocyte cell types during iCMs induction.
MM408, an inhibitor of Mll1-WDR5 interaction,
is able to increase iCM formation by inhibiting
adipogenesis. Our studies reported here point to a new
direction in enhancing iCM conversion. Instead of
boosting iCM conversion directly by increasing
the cardiac gene expression, actively incorporating
strategies to inhibit conversion of fibroblasts into other
related cell types may also increase iCM formation.
Mechanistically, this MM408 mediated Mll1
inhibition is achieved, at least partially, by blocking the
expression of Mll1 target Ebf1, a key gene involved
in adipocytes differentiation [35]. Our discovery is
consistent with a number of Mll1 studies in cell lineage
development, which show that Men1 directly targets
Pparg [36] through Mll to facility adipogenesis. Our
results also show that in addition to Pparg, Ebf1 is also
involved in adipocyte differentiation as a direct Mll1
target. Future research focusing on the epigenetic
changes during the whole reprogramming process will
reveal the mechanistic details of how Mll1 regulates
cardiac reprogramming.
Our study shows that MGT not only induces iCM
but also increases adipocyte formation. The molecular
mechanism of MGT-mediated adipogenesis will be
explored in the future. One potential reason might be
that iCM and adipocytes are developmentally related.
It has been shown that Myf5 positive myogenic
precursors can differentiate into both adipocytes and
muscle cells. Mature adipocytes [37] and adipocyte
derived stem cells [38] possess the ability to differentiate
into functional cardiomyocytes. These studies suggest
close functional and original connections between
adipocyte and muscle cell. Indeed, the observation that
induction of unexpected cell types in reprogramming
appears to be a common theme, as has been reported
recently in neuron [19] and iPSC [20] reprogramming.
We expect that applications of chemical approaches
for reprogramming and transdifferentiation represent a
highly desirable strategy in heart regeneration to treat
heart attack and associated heart failure. In fact,
a couple of recent studies show the feasibility that
cardiomyocyte-like cells can be obtained from
embryonic fibroblasts with only small molecule
treatment in vitro [39, 40]. Future studies combining
MM408 described here with small molecules and
candidate molecules identified from other studies
should convert fibroblasts into functional and more
mature beating cardiomyocytes with high efficiency.
Materials and Methods
Mouse lines
The transgenic mice harboring GFP under control of
α-MHC promoter was used to derive MEFs as previous
reported [7]. Another transgenic mice harboring mCherry under
control of modified α-MHC promoter was purchased from
Jackson’s lab (021577).
All animal-related procedures were approved by the
Institutional Animal Care and Use Committee of the University
of Michigan and are consistent with the National Institutes of
Health Guide for Use and Care of Animals.
Plasmids
The retroviral polycistronic constructs vectors encoding
mouse Mef2c, Gata4 and Tbx5 in pMXs based vectors were
constructed as described previously [7]. DNA fragment
containing Mef2c, Gata4 and Tbx5 sequentially were separated
by oligonucleotides encoding P2A and T2A peptides
constructed into a polycistronic constructs vector. The shRNA
lentivirus vector for Ebf1 (pGipZ, V2LMM-20601), Mll1
(pGipZ, V2LMM-96428) were from Vector Core of University
of Michigan.
Primary cell isolation
MEFs (isolated at E13.5) were prepared as previously
described. Briefly, embryos were harvested from transgenic mice
of α-MHC-GFP or α-MHC-mCherry at 13.5 days post coitum
followed by decapitation and removal of internal organs,
including the heart. The tissue was minced and digested with
TrypLE Express Enzyme (Thermo Fisher Scientific, Waltham,
MA, USA). Cells were resuspended inMEFs medium (10% FBS
and 2 mM L-glutamine contained DMEM medium) and plated
onto one 10 cm dish per embryo. Cells were regularly passaged
at 1:3 (passage 1). Passage 3 MEFs were used for
reprogramming.
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Inhibitor information
Men1 inhibitor was from Active Biochem (MI503, A-1399),
Suv39h1 inhibitor (chaetocin, sc-200893) was from Santa Cruz,
Mll1/WDR5 inhibitor (MM408) was from Dr. Shaomeng
Wang’s lab.
Retrovirus and lentivirus preparation
Retrovirus vectors were packaged into Plat-E cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) to deliver
10 μg in 1.5 ml Opti-MEM (Invitrogen) to 80% confluent 10 cm
plates of Plat-E cells with 6 ml of Opti-MEM. 4-6 h later,
Opti-MEM was changed into 10ml fresh MEFs medium.
Forty-eight hours and seventy-two hours after transfection, viral
medium was harvested twice and filtered through a 0.45-mm
cellulose filter. The harvested virus containing medium was
added 1/5 vol of 40% PEG8000 solution to make a final
concentration of 8% PEG8000. The mixture was kept at 4 °C
overnight and spined at 3000 g, 4 °C, 30 min to get concentrated
white pellet. FreshMEFs medium was added to resuspend virus.
The viral supernatant was mixed with polybrene (Sigma,
St Louis, MO, USA) to a final concentration of 8 μg ml− 1.
Lentiviral vectors were packaged into HEK293T cells
(ATCC) using Lipofectamine 2000 (Invitrogen) to deliver 10 μg
of the lentiviral backbone plasmid, 6 μg psPAX2, and 4 μg
pMD2.G in 1.5 ml Opti-MEM (Invitrogen) to 80% confluent
10 cm plates of 293 cells with 6 ml of Opti-MEM. 4-6 h later,
Opti-MEM was changed into 10 ml fresh MEFs medium. The
virus was harvested as descried before.
Direct conversion of fibroblasts to iCMs
Direct conversion of MEFs was completed using a protocol
similar to that previously described [7]. Fresh fibroblasts were
plated on tissue culture dishes at a density of 10 000 cells cm−2
before transduction. Fibroblasts were infected with freshly made
viral mixture containing polybrene (Sigma) 24 h post plating.
Twenty-four hours later, the viral medium was replaced with
induction medium composed of DMEM/199 (4:1) (Gibco,
Waltham, MA, USA), 10% FBS (Gemini, West Sacramento,
CA, USA) and antibiotics (Gibco). Medium was changed every
2–3 days until cells were examined.
Immunocytochemistry
Samples were fixed using 4% PFA with 0.1% TritonX-100.
The following primary antibodies were used: mouse anti-cardiac
Troponin T (Thermo Scientific, Waltham, MA, USA), mouse
anti sarcomeric a-actinin (Abcam, Waltham, MA, USA). For
Oil Red O staining, dishes were washed in PBS three times and
cells fixed in 3.7% formaldehyde for 1h, followed by staining
with Oil Red 0 for 1h; after staining, plates were washed twice in
water and photographed. The final Oil Red O solution used
consists of 60% original Oil Red O solution (0.3% Oil Red O in
60% isopropanol (Sigma)) diluted with 40% DI water.
Flow cytometry
For fluorescence measurements only, data from 10 000 single
cell events were collected using a standard MoFlo Astrios flow
cytometer (Immunocytometry Systems; Becton Dickinson,
Detroit, MI, USA). Data were analyzed using Summit (Becton
Dickinson).
Quantitative real time PCR (QPCR)
Total RNA was extracted using Trizol Reagent (Invitrogen)
according to the manufacturer’s instructions. RNA integrity was
determined using formaldehyde denaturalization agarose gel
electrophoresis. RNA concentrations were measured with the
smartspec plus spectrophotometer (BioRad, Hercules, CA,
USA). RNA was reverse transcribed using iScript cDNA
Synthesis Kit (BioRad). QPCR was performed using StepOne
Real-Time PCR System (Thermo Fisher Scientific).
Primer oligonucleotides were synthesized by Invitrogen and
are listed in Supplementary Table S2.
Statistical analysis
Results were presented as mean± s.e.m. Statistical
significance between groups was analyzed by one-way ANOVA
followed by the Student–Newman–Keuls multiple comparisons
tests. A P-value of o0.05 was considered significant. Each
experiment was performed at least twice.
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